EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CRISPR Therapeutics AG's Enterprise Value is €2,648.6 Mil.
CRISPR Therapeutics AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-156.4 Mil. Therefore, CRISPR Therapeutics AG's EV-to-FCF for today is -16.94.
The historical rank and industry rank for CRISPR Therapeutics AG's EV-to-FCF or its related term are showing as below:
STU:1CG'
s EV-to-FCF Range Over the Past 10 Years
Min: -62.95 Med: -7.3 Max: 196.76
Current: -16.87
During the past 10 years, the highest EV-to-FCF of CRISPR Therapeutics AG was 196.76. The lowest was -62.95. And the median was -7.30.
STU:1CG's EV-to-FCF is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 6.305
vs STU:1CG: -16.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CRISPR Therapeutics AG's EV-to-FCF
For the Biotechnology subindustry, CRISPR Therapeutics AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's EV-to-FCF falls into.
CRISPR Therapeutics AG's current Enterprise Value is €2,648.6 Mil.
CRISPR Therapeutics AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-156.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (STU:1CG) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CRISPR Therapeutics AG's PE Ratio for today is calculated as:
CRISPR Therapeutics AG's share price for today is €40.80.
CRISPR Therapeutics AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.506.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CRISPR Therapeutics AG EV-to-FCF Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (STU:1CG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:1CG has been successfully added to your 